In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history. “We’re not just a Keytruda company, we’re an oncology company,” he noted. HPV is an area where Merck continues to invest, and it’s also focusing on the next generation of GLP-1’s.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- Is There an Opportunity in Moderna Stock’s Volatility?
- Drugmakers Raise the Prices on 583 Products to Start 2025
- Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz
- Trump Trade: New administration to invest $20B to build data centers